about
hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicineInduction of multipotency in umbilical cord-derived mesenchymal stem cells cultivated under suspension conditions.Alternative sources of pluripotent stem cells: ethical and scientific issues revisited.Nanotopographical Surfaces for Stem Cell Fate Control: Engineering Mechanobiology from the BottomHuman pluripotent stem cells: Prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair.Embryonic and induced pluripotent stem cells: understanding, creating, and exploiting the nano-niche for regenerative medicine.Current protocols in the generation of pluripotent stem cells: theoretical, methodological and clinical considerations.Musings on genome medicine: is there hope for ethical and safe stem cell therapeutics?The immune boundaries for stem cell based therapies: problems and prospective solutions.Induced human pluripotent stem cells: promises and open questions.Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum.Induced pluripotent stem cells in regenerative medicine: an argument for continued research on human embryonic stem cells.Assessing the value of autologous and allogeneic cells for regenerative medicine.Translational prospects for human induced pluripotent stem cells.Systems biology discoveries using non-human primate pluripotent stem and germ cells: novel gene and genomic imprinting interactions as well as unique expression patterns.Personalized cardiac regeneration by stem cells-Hype or hope?Graphene nanomaterials as biocompatible and conductive scaffolds for stem cells: impact for tissue engineering and regenerative medicine.Positive selection of Wharton's jelly-derived CD105(+) cells by MACS technique and their subsequent cultivation under suspension culture condition: A simple, versatile culturing method to enhance the multipotentiality of mesenchymal stem cells.Establishment of a Brazilian line of human embryonic stem cells in defined medium: implications for cell therapy in an ethnically diverse population.Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery.Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?Developing safe therapies from human pluripotent stem cells.Stem cell policy exceptionalism: proceed with caution.Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.Engineering Complex Tissues
P2860
Q26751506-4F67380C-26A6-4885-94D6-7BF59A5E46F7Q34099882-50E00D43-B55B-4D2D-B4A4-2783379C9E00Q35082744-74DF7E6D-9FAA-4A31-9855-1D2D3336C6E3Q35379721-48524D23-7F53-45D8-9BBE-9D16B2869E8CQ36279078-C2FD5C54-0C68-446A-9B31-6558AA5DFDAAQ36723260-21769A39-6E75-4914-AABE-EFBF08516251Q37194068-E016A2F6-03F0-4D42-A7F5-4E73ED46BD27Q37279705-D79CDF1C-44B7-4BA3-BEAA-61C190DE3A11Q37310625-405AA4CD-7EE0-4B81-93DF-9B830F646F98Q37532537-B4D4038C-B772-4525-B387-E64C305F695BQ37542235-377B7AE2-2FB7-4421-B900-197D72C7B757Q37598915-CB22E2C7-F3E8-4854-9801-3E31408230ABQ37630522-B1E754A6-578A-40CA-8470-2292D4AD59E2Q37772899-446A9C8D-D1D6-45D3-8E13-B0C4D903CD8DQ37779123-E14C8369-C7BB-4C9C-9C56-65C2701DA075Q38063951-70A4B1F8-F114-4F85-B37F-BF8BE12FB42FQ38219380-57C12926-E045-4490-BF3A-D6A97133E7F5Q39145866-A2CA9E98-9005-455A-A9CB-8B1F2CF3B124Q39666135-45D4C8A3-BC60-4FD2-B871-68A954C54AA1Q39856747-E123A40B-667C-431B-BB94-25B90C2056CDQ41122141-FA9CAB1C-D3D0-43BB-A21F-EF4829B0790FQ46082787-9694F833-EFD9-4A7C-AFD4-8D426D06B2EBQ46429812-9C162E2E-11BE-41C3-B93F-31EAD141056AQ47609134-A43E2FF8-9AA0-4A27-94E8-4CE1AC973E44Q57395890-27BB0A0F-7C16-499B-B49A-4E60468F7C33
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regulatory issues for personalized pluripotent cells.
@en
Regulatory issues for personalized pluripotent cells.
@nl
type
label
Regulatory issues for personalized pluripotent cells.
@en
Regulatory issues for personalized pluripotent cells.
@nl
prefLabel
Regulatory issues for personalized pluripotent cells.
@en
Regulatory issues for personalized pluripotent cells.
@nl
P2860
P1433
P1476
Regulatory issues for personalized pluripotent cells.
@en
P2093
Mahendra Rao
Maureen L Condic
P2860
P304
P356
10.1634/STEMCELLS.2008-0421
P577
2008-07-31T00:00:00Z